



Immuron Hyperimmune Oral Antibody Affirmed Safe by International Expert Panel

NEW YORK and MELBOURNE, April 17. Immuron Ltd today announced that its hyperimmune oral antibody formulation derived from cow's immune milk has been self-affirmed with "Generally Recognized as Safe" or GRAS status by an independent expert panel of internationally recognized physician experts. As a result of the Expert Panel determination, Immuron's BCP nutritional platform is safe for use as an ingredient in food products, paving its way to be marketed for use in already established nutritionals and functional foods, or as a medical food, based upon scientific data, especially from clinical efficacy studies already underway.

According to the FDA, self-affirmed GRAS status is awarded to any substance that is generally recognized among qualified experts as having been adequately shown to be safe under conditions of its intended use. The expert panel was composed of recognized physician experts in pediatric immunology, infectious disease, nutrition and clinical trials. They assessed published safety data from a large number of clinical and toxicology studies in reaching their conclusion.

Dr. Zeil Rosenberg, Immuron CEO, noted "With GRAS safety affirmation by such a distinguished panel, and multiple ongoing clinical studies being developed in the US, Israel and Australia, we have initiated partnership discussions with major consumer nutrition focused companies interested in HIV/AIDS, influenza and metabolic syndrome. These are important areas where our antibodies can have major health benefit."

Dr. Oren Fuerst, the Head of Business Development, noted: "In addition to the impact on our greatly enhanced ability to market medical food for specific indications, the GRAS affirmation would now allow us to address new markets such as partnerships with major food manufacturers for the creation of unique and patented functional foods as well as opening up to us the entire emerging segment of pet animal health."

About Immuron

[Immuron Limited](#) (IMC.AX ; OTCQX: IMROY) is a biopharmaceutical company focused on oral immunotherapy using dairy-derived health products. Immuron's antigen-primed antibody manufacturing technology enables it to rapidly develop antibody and other protein-based oral therapies to a range of important infectious and immune-mediated diseases, including Metabolic syndrome, Influenza, cancer therapy-related GI tract Mucositis, and HIV/AIDS related immune activation.

Contact Information:

Dr. Oren Fuerst, Head of Business Development
oren@immuron.com
Direct +1 646 259 3321
Australia +61 3 9018 5712